ClinicalTrials.gg

TargetBeta

CD38

CD38 molecule · also cADPR1 · CD molecules

11 programs in company-led studies act on CD38, from 10 companies: 6 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (9 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
daratumumabruleJohnson & Johnsonphase 44410 running–NCIt
lumrotatugruleKeymed Biosciencesphase 3108 running–NCIt
felzartamabruleBiogenphase 3157 running–NCIt
isatuximabruleSanofiphase 3236 running–NCIt
Anti-CD38 Monoclonal Antibody SCTC21CruleSinocelltech Groupphase 355 running–NCIt
mezagitamabruleTakedaphase 3114 running–NCIt
sanritatugruleHangzhou Sumgen Biotechphase 354 running–NCIt
CID-103ruleCASI Pharmaceuticalsphase 232 running–NCIt
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 222 runningCD3E, TNFRSF17the company's pipeline
Anti-CD38 Monoclonal AntibodyruleChongqing Genrix Biopharmaceuticalphase 211 running–NCIt
Anti-CD38 Antibody-drug Conjugate ABBV-438AbbViephase 111 running–the company's pipeline

Also acted on by the same programs

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.